Uncategorized
FDA accepts investigational new drug application for Ocugen’s dry eye treatment
The FDA has accepted an investigational new drug application for OCU310, a topical formulation for the treatment of dry eye disease, according to a press release from Ocugen.Ocugen has also dosed its first patient in a randomized, placebo-controlled, double-masked, multicenter, proof of concept study to assess the tolerability and preliminary efficacy of OCU310 (brimonidine/steroid combination therapy) in dry eye.